Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.

Autor: Pettus JH; University of California San Diego, San Diego, CA jpettus@ucsd.edu., D'Alessio D; Duke University Medical Center, Durham, NC., Frias JP; National Research Institute, Los Angeles, CA., Vajda EG; Ligand Pharmaceuticals Incorporated, San Diego, CA., Pipkin JD; Ligand Pharmaceuticals Incorporated, San Diego, CA., Rosenstock J; Dallas Diabetes Research Center at Medical City, Dallas, TX., Williamson G; Medpace, Cincinnati, OH., Zangmeister MA; Medpace, Cincinnati, OH., Zhi L; Ligand Pharmaceuticals Incorporated, San Diego, CA., Marschke KB; Ligand Pharmaceuticals Incorporated, San Diego, CA.

Publikováno v: Diabetes care [Diabetes Care] 2020 Jan; Vol. 43 (1), pp. 161-168. Date of Electronic Publication: 2019 Nov 06.